Compare Credo Technology Group Holding Ltd (CRDO) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Credo Technology Group Holding Ltd vs Gilead Sciences, Inc. — how do they compare? Credo Technology Group Holding Ltd trades at $216.55 (market cap $39.82B), while Gilead Sciences, Inc. trades at $151.13 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 4.6× Credo Technology Group Holding Ltd's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Credo Technology Group Holding Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Credo Technology Group Holding Ltd for 22 Days and Gilead Sciences, Inc. for 111 Days on average.
| CRDO | GILD | |
|---|---|---|
Market Cap | $39.82B | $182.40B |
Volume | 9,451,558 | 4,469,821 |
Sector | Technology | Health |
52-Week High | $302.52 | $155.80 |
52-Week Low | $87.81 | $116.74 |
Typical Hold Time | 22 Days | 111 Days |
Enterprise Value | $39.08B | $205.46B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $216.55, down 1.57% on the day, but maintains strong bullish momentum with triple-digit revenue growth driven by AI infrastructure demand. The stock shows robust fundamentals with 33.83% net margins and consistent earnings beats, though valuation metrics remain elevated with a P/E of 74.6. Technical indicators suggest bullish momentum with support at $204 and resistance at $222.
Outlook remains positive given explosive AI-driven growth and strong analyst support (87.5% buy ratings), but premium valuation and customer concentration present execution risks. The consensus price target of $267.33 implies 23% upside potential from current levels, supported by expanding optical product offerings and hyperscaler relationships.
Gilead Sciences (GILD) trades at $151.17, up 2.94% recently, with strong technical momentum and bullish moving averages. The company shows robust revenue growth to $29.44B in 2025 and beat earnings estimates in three consecutive quarters, though net income margin turned negative at -10.64% for 2026. Recent developments include expanded HIV drug access in Latin America via a PAHO partnership, positioning Gilead for growth in its core franchises.
Gilead presents a mixed outlook with solid operational cash flow and analyst bullishness (65.5% buy ratings) offset by profitability concerns and high debt levels. The stock's current price aligns with the consensus target of $151.57, suggesting limited near-term upside. Key risks include execution in oncology pipeline expansion and reliance on HIV treatment revenues amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
